184 related articles for article (PubMed ID: 36051634)
1. Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases.
Kiltz U; Tsiami S; Baraliakos X; Andreica I; Kiefer D; Braun J
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221119593. PubMed ID: 36051634
[TBL] [Abstract][Full Text] [Related]
2. Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study.
Schmalzing M; Kellner H; Askari A; De Toro Santos J; Vazquez Perez-Coleman JC; Foti R; Jeka S; Haraoui B; Allanore Y; Peichl P; Oehri M; Rahman M; Furlan F; Romero E; Hachaichi S; Both C; Brueckmann I; Sheeran T
Adv Ther; 2024 Jan; 41(1):315-330. PubMed ID: 37950790
[TBL] [Abstract][Full Text] [Related]
3. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study.
Tweehuysen L; Huiskes VJB; van den Bemt BJF; Vriezekolk JE; Teerenstra S; van den Hoogen FHJ; van den Ende CH; den Broeder AA
Arthritis Rheumatol; 2018 Sep; 70(9):1408-1418. PubMed ID: 29609207
[TBL] [Abstract][Full Text] [Related]
4. The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases.
Bruni C; Gentileschi S; Pacini G; Baldi C; Capassoni M; Tofani L; Bardelli M; Cometi L; Cantarini L; Nacci F; Vietri M; Bartoli F; Fiori G; Frediani B; Matucci-Cerinic M
Ther Adv Musculoskelet Dis; 2020; 12():1759720X20964031. PubMed ID: 33133246
[TBL] [Abstract][Full Text] [Related]
5. Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study.
Pope J; Hall S; Bombardier C; Haraoui B; Jones G; Naik L; Etzel CJ; Ramey DR; Infante R; Miguelez M; Falcao S; Sahakian S; Wu D
Adv Ther; 2022 Nov; 39(11):5259-5273. PubMed ID: 36136243
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
[TBL] [Abstract][Full Text] [Related]
7. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G
Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316
[TBL] [Abstract][Full Text] [Related]
8. Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study.
Larid G; Baudens G; Dandurand A; Coquerelle P; Goeb V; Guyot MH; Marguerie L; Maury F; Veillard E; Houvenagel E; Salmon JH; Flipo RM; Gervais E
Front Med (Lausanne); 2022; 9():989514. PubMed ID: 36275803
[TBL] [Abstract][Full Text] [Related]
9. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
Glintborg B; Loft AG; Omerovic E; Hendricks O; Linauskas A; Espesen J; Danebod K; Jensen DV; Nordin H; Dalgaard EB; Chrysidis S; Kristensen S; Raun JL; Lindegaard H; Manilo N; Jakobsen SH; Hansen IMJ; Dalsgaard Pedersen D; Sørensen IJ; Andersen LS; Grydehøj J; Mehnert F; Krogh NS; Hetland ML
Ann Rheum Dis; 2019 Feb; 78(2):192-200. PubMed ID: 30396903
[TBL] [Abstract][Full Text] [Related]
10. Real-world use of an etanercept biosimilar including selective
Cooksey R; Brophy S; Kennedy J; Seaborne M; Choy E
Rheumatol Adv Pract; 2022; 6(2):rkac056. PubMed ID: 35910710
[TBL] [Abstract][Full Text] [Related]
11. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
Griffiths CEM; Thaçi D; Gerdes S; Arenberger P; Pulka G; Kingo K; Weglowska J; ; Hattebuhr N; Poetzl J; Woehling H; Wuerth G; Afonso M
Br J Dermatol; 2017 Apr; 176(4):928-938. PubMed ID: 27787890
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study.
Carballo N; Pérez García C; Grau S; Monfort J; Durán-Jordà X; Echeverría-Esnal D; Ferrández O
Front Pharmacol; 2022; 13():980832. PubMed ID: 36263118
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
[TBL] [Abstract][Full Text] [Related]
14. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
Gerdes S; Thaçi D; Griffiths CEM; Arenberger P; Poetzl J; Wuerth G; Afonso M; Woehling H
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):420-427. PubMed ID: 28960486
[TBL] [Abstract][Full Text] [Related]
15. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
Nabi H; Hendricks O; Jensen DV; Loft AG; Pedersen JK; Just SA; Danebod K; Munk HL; Kristensen S; Manilo N; Colic A; Linauskas A; Thygesen PH; Christensen LB; Kalisz MH; Lomborg N; Chrysidis S; Raun JL; Andersen M; Mehnert F; Krogh NS; Hetland ML; Glintborg B
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36418087
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost-savings.
Deakin CT; Littlejohn GO; Griffiths H; Ciciriello S; O'Sullivan C; Smith T; Youssef P; Bird P;
Intern Med J; 2024 May; 54(5):795-801. PubMed ID: 38009675
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study.
Matucci-Cerinic M; Allanore Y; Kavanaugh A; Buch MH; Schulze-Koops H; Kucharz EJ; Woehling H; Babic G; Poetzl J; Davis A; Schwebig A
RMD Open; 2018; 4(2):e000757. PubMed ID: 30487998
[TBL] [Abstract][Full Text] [Related]
18. Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.
Feist E; Baraliakos X; Behrens F; Thaçi D; Plenske A; Klaus P; Meng T
Rheumatol Ther; 2024 Apr; 11(2):331-348. PubMed ID: 38308727
[TBL] [Abstract][Full Text] [Related]
19. Non-medical switching from reference to biosimilar etanercept - no evidence for nocebo effect: a retrospective analysis of real-life data.
Kiltz U; Pudelko JC; Tsiami S; Baraliakos X; Braun J
Clin Exp Rheumatol; 2021; 39(6):1345-1351. PubMed ID: 33427615
[TBL] [Abstract][Full Text] [Related]
20. Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis.
Simpson EL; Ren S; Hock ES; Stevens JW; Binard A; Pers YM; Archer R; Paisley S; Stevenson MD; Herpin C; Ghabri S
Int J Technol Assess Health Care; 2019 Jan; 35(1):36-44. PubMed ID: 30722803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
